Patents Examined by Yunsoo Kim
  • Patent number: 10881718
    Abstract: Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 5, 2021
    Assignee: The University of Kansas
    Inventors: Cory Berkland, Joshua Sestak, Teruna J. Siahaan
  • Patent number: 10875922
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Ying Yang, Sreedhara Alavattam
  • Patent number: 10849977
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: December 1, 2020
    Assignee: EAGLE BIOLOGICS, INC.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10851150
    Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: December 1, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
  • Patent number: 10835602
    Abstract: The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 17, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Parshad, Dorthe Kot Engelund
  • Patent number: 10828351
    Abstract: A liposomal vaccine composition comprises a ?-amyloid (A?)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 10, 2020
    Assignee: AC Immune SA
    Inventors: Emma Fiorini, Marija Vukicevic Verhille, Maria Pihlgren Bosch
  • Patent number: 10821184
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 3, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10821183
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 3, 2020
    Assignee: Eagle Biologics, Inc.
    Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 10808021
    Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: October 20, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kirk J. Leister, Eugene J. Schaefer, Ronald Charles Bates, Elizabeth A. Bramhall, David Michael Didio, Robert Donaldson, Alan R. Flesher, Helen Gray Haggerty, David Henry Kirkley, John Malcolm Tabor, Lee K. Tay, Pallaiah Thammana, Ajoy Velayudhan, David Edward Smolin, Reb J. Russell, Thomas James Vanden Boom, Dean Woodrow Brownell, Jeffrey Schrimsher, Joyce Patricia Whitehead
  • Patent number: 10799585
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 13, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10792359
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10786567
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 29, 2020
    Assignees: Suzhou Suncediabiopharmaeuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10786566
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: September 29, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10780163
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: September 22, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10772959
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10772960
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 10765736
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: September 8, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10752696
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 25, 2020
    Assignee: GENENTECH, INC.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Patent number: 10753934
    Abstract: The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 25, 2020
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Michael Tsionsky, Eli N. Glezer, Selen Stromgren, George Sigal, Jonathan K. Leland, Mark A. Billadeau, Svetlana Leytner, Mark Martin, Larry Helms
  • Patent number: 10722579
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 28, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne